Skip to search formSkip to main contentSkip to account menu

BMY 28090

Known as: BMY-28090, BMY28090 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
SummaryBMY-28090 is a novel actinomycete fermentation derived antitumor agent. The cytotoxic effect of BMY-28090 was evaluated in… 
2004
2004
SummaryPurpose: To determine the response rate of patients withrefractory/relapsed non-Hodgkin's lymphoma to treatment with… 
2004
2004
SummaryThe compound BMY-28090 (elsamicin A) is a new fermentation product with antitumor properties, which has the same aglycone… 
2004
2004
Elsamitrucin (BMY-28090) a novel fermentation product has demonstrated pre-clinical anti-tumour activity against a number of cell… 
1992
1992
Elsamitrucin (BMY-28090) is an antitumor antibiotic first described in 1985 that has significant oncolytic activity against a…